Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Elina Asikanius Noel Jean Milpied Franck Morschhauser Guillaume Cartron Gilles Salles Catherine Thieblemont |
| Publication date | March 19, 2012 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |